Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 15/20 | 0.73 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.51 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28703245 | 0.86 | NFE2L2 (0.76) | NFE2L2TRPA1CYP19A1CYP1A1CYP1A2 | |
| SCHEMBL31689790 | 0.85 | NFE2L2 (0.55) | NFE2L2TRPA1CYP19A1CYP1A1CYP1A2 | |
| SCHEMBL31689795 | 0.85 | NFE2L2 (0.55) | NFE2L2TRPA1CYP19A1CYP1A1CYP1A2 | |
| SCHEMBL20995869 | 0.85 | NFE2L2 (1.00) | NFE2L2TRPA1CYP19A1CYP1A1CYP1A2 | |
| SCHEMBL20995868 | 0.85 | NFE2L2 (1.00) | NFE2L2TRPA1CYP19A1CYP1A1CYP1A2 | |
| SCHEMBL26746210 | 0.78 | NQO2 (0.65) | NFE2L2TRPA1CYP19A1CYP1A1CYP1A2 | |
| SCHEMBL9168164 | 0.77 | NFE2L2 (0.88) | NFE2L2TRPA1CYP19A1CYP1A1CYP1A2 | |
| SCHEMBL9168170 | 0.77 | NFE2L2 (0.88) | NFE2L2TRPA1CYP19A1CYP1A1CYP1A2 | |
| SCHEMBL28715871 | 0.75 | NFE2L2 (0.76) | NFE2L2TRPA1CYP19A1CYP1A1CYP1A2 | |
| SCHEMBL15641649 | 0.75 | NFE2L2 (0.65) | NFE2L2TRPA1CYP19A1CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023172-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | TRUJILLO KRISTINA (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023172-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | NFKBIA, IKBKB, NFKB2 | NFE2L2 9/4885TRPA1 605/4885CYP19A1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.